UB Paderborn / Katalog / Suche / in CDI

1 – 21 von 21

Sortiert nach

Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In Vivo

Antimicrobial Agents and Chemotherapy, 2010-01, Vol.54 (1), p.491-501

2010

Volltextzugriff (PDF)

Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naïve Patients Infected with Non-B HIV-1 Subtypes

Antimicrobial Agents and Chemotherapy, 2010-02, Vol.54 (2), p.728-733

2010

Volltextzugriff (PDF)

Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients

AIDS (London), 2008-10, Vol.22 (16), p.2212-2214

2008

Volltextzugriff (PDF)

HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs

Journal of antimicrobial chemotherapy, 2012-10, Vol.67 (10), p.2323-2326

2012

Volltextzugriff (PDF)

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients

Journal of antimicrobial chemotherapy, 2009-04, Vol.63 (4), p.795-804

2009

Volltextzugriff (PDF)

Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals

AIDS (London), 2010-09, Vol.24 (15), p.2313-2321

2010

Volltextzugriff (PDF)

Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments

AIDS (London), 2014-02, Vol.28 (4), p.487-491

2014

Volltextzugriff (PDF)

Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors

Journal of antimicrobial chemotherapy, 2010-11, Vol.65 (11), p.2305-2318

2010

Volltextzugriff (PDF)

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype

Journal of antimicrobial chemotherapy, 2011-12, Vol.66 (12), p.2827-2830

2011

Volltextzugriff (PDF)

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists

Journal of antimicrobial chemotherapy, 2010-04, Vol.65 (4), p.749-751

2010

Volltextzugriff (PDF)

A Single Amino-Acid Change in a Highly Conserved Motif of gp41 Elicits HIV-1 Neutralization and Protects Against CD4 Depletion

Clinical infectious diseases, 2013-09, Vol.57 (5), p.745-755

2013

Volltextzugriff (PDF)

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients

Journal of antimicrobial chemotherapy, 2011-07, Vol.66 (7), p.1481-1483

2011

Volltextzugriff (PDF)

Risk factors for raltegravir resistance development in clinical practice

Journal of antimicrobial chemotherapy, 2012-10, Vol.67 (10), p.2494-2500

2012

Volltextzugriff (PDF)

Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug

Journal of antimicrobial chemotherapy, 2009-11, Vol.64 (5), p.1087-1090

2009

Volltextzugriff (PDF)

E138K and M1841 mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure

AIDS (London), 2012, Vol.26 (13), p.1619-1624

2012

Volltextzugriff (PDF)

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes

Antiviral therapy, 2009, Vol.14 (1), p.123-129

2009

Volltextzugriff (PDF)

Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients

AIDS (London), 2007-04, Vol.21 (7), p.871-873

2007

Volltextzugriff (PDF)

Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease

Journal of antimicrobial chemotherapy, 2008-11, Vol.62 (5), p.905-908

2008

Volltextzugriff (PDF)

Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors

AIDS (London), 2006-01, Vol.20 (2), p.287-289

2006

Volltextzugriff (PDF)

Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with k65r mutation associated with thymidine analogue mutations or L74V substitution

AIDS (London), 2005-03, Vol.19 (6), p.630-632

2005

Volltextzugriff (PDF)

Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir)

Clinics and research in hepatology and gastroenterology, 2012-06, Vol.36 (3), p.214-221

2012

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Aktive Filter

KollektionElsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)

ThemaInfectious Diseases

ThemaViral Diseases Of The Lymphoid Tissue And The Blood. Aids

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In Vivo

Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naïve Patients Infected with Non-B HIV-1 Subtypes

Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients

HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients

Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals

Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments

Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists

A Single Amino-Acid Change in a Highly Conserved Motif of gp41 Elicits HIV-1 Neutralization and Protects Against CD4 Depletion

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients

Risk factors for raltegravir resistance development in clinical practice

Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug

E138K and M1841 mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes

Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients

Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease

Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors

Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with k65r mutation associated with thymidine analogue mutations or L74V substitution

Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir)

Aktive Filter

Suchergebnisse filtern